N/A
Completed N=708
A Study to Learn About the Benefit of Rimegepant Versus Triptans in Migraine Buddy App Users.
Source: ClinicalTrials.gov NCT06532357 ↗Enrolled (actual)
708
Serious AEs
—
Results posted
Aug 2025
Primary outcomePrimary: Number of Participants Classified as Per Responses for Satisfaction of Pain Intensity — 539; 625; 130; 178 Participants
Summary
The purpose of this study is to collect information of the US users from the Migraine Buddy app between 20 October 2023 and 20 May 2024. Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications) and completed a survey were eligible for this study. Acute treatment is a short-term treatment. The aim of this retrospective analysis was to learn about the user´s satisfaction with Nurtec or the triptan. The level of satisfaction with Nurtec will be compared to the level of satisfaction with triptans. The benefit of this study is the real-life setting of the information collected. This means that the users were using the Migraine Buddy app for tracking their migraines in real life.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Classified as Per Responses for Satisfaction of Pain Intensity |
539; 625; 130; 178; 39; 42 | — |
| PRIMARY Number of Participants Classified as Per Responses for Satisfaction With of Attack Duration |
524; 571; 145; 222; 39; 52 | — |
| PRIMARY Number of Participants Classified as Per Responses for Satisfaction With Speed of Action |
506; 524; 154; 272; 48; 49 | — |
| PRIMARY Number of Participants Classified as Per Responses for Satisfaction With Migraine-Induced Cognitive Impact |
430; 384; 237; 377; 41; 84 | — |
| PRIMARY Number of Participants Classified as Per Responses for Satisfaction With Relief of Other Symptoms |
418; 478; 243; 301; 47; 66 | — |
| PRIMARY Number of Participants Classified as Per Responses for Satisfaction of Tolerability |
385; 554; 50; 229; 12; 62 | — |
Eligibility Criteria
Inclusion Criteria
- Patients who used Nurtec and/or triptans as an acute treatment for migraine, with or without a background of preventive treatment (anti-CGRP, Botox or oral migraine preventive medications).
- Male or female participants with migraine
- Having consented to the anonymous use of their data for research
- Currently using Nurtec and/or triptans to treat migraine attacks
Exclusion Criteria
- Users who did not report using either medication for which they complete the survey within 60 days prior to the survey.
Data sourced from ClinicalTrials.gov (NCT06532357). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.